Chinese Pharma Firm WuXi AppTec Shares Rise After Strong Results, Guidance Raise
By Jason Chau
WuXi AppTec's shares rose Monday morning after the Chinese pharmaceutical company reported strong third-quarter earnings and again raised its guidance for the year.
The stock rose more than 7% in Hong Kong and 6% in Shanghai before paring gains. H-shares were last at HK$116.60, while A-shares were at CNY106.98.
That came after the Shanghai-based drugmaker, which provides services including drug research and discovery, posted a 83% on-year rise in quarterly net profit. Revenue climbed 15%.
WuXi attributed the results to the performance of its core contract research, development, and manufacturing business, noting continued revenue growth and improved efficiency in late-stage clinical and commercialization projects.
It also booked gains from the partial divestment of its cancer treatment-focused subsidiary, a filing showed.
Expressing confidence in the outlook for demand for its services and CRDMO business model, the company said it has further raised its full-year guidance. WuXi now sees annual revenue from continuing operations at 43.5 billion yuan to 44.0 billion yuan, up 17% to 18%.
The strategic divestment of clinical research services is another plus, letting the firm focus fully on CRDMO, said chairman and chief executive Dr. Ge Li.
Earlier this month, it sold two clinical research units to Asia-focused private-equity firm Hillhouse Investment Management. The transaction is pending regulatory approval.
Citi analysts estimate that gains from the sale could exceed 10% of the company's 2024 net profit. They maintained a buy call on WuXi's stock.
Write to Jason Chau at jason.chau@wsj.com
(END) Dow Jones Newswires
October 27, 2025 01:05 ET (05:05 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Growth Stocks to Buy While They’re Still Undervalued
The 10 Best Companies to Invest in Now
Your Year-End Financial Checklist: 5 Things to Tackle Before 2027
These Overvalued Stocks Have Plenty of Room to Fall
United States